Abstract
GC-rich stretches in the DNA minor groove are the established intracellular targets for the aureolic acid group of antibiotics such as olivomycin A and its semisynthetic analogue olivamide. We demonstrated here that both antibiotics at nanomolar concentrations inhibited transcription of the c-Myc oncogene in cultured human tumor cells. The mechanism of transcriptional inhibition did not require the full-length binding site for Sp1, a GC-dependent transcriptional factor. GC quartets with the nucleotide sequences optimal for drug binding are sufficient for c-Myc transcriptional block by the aureolic acid derivatives.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Brikenshtein, V.Kh., Pitina, L.R., Barenboim, G.M., et al., Stereochemistry and kinetics of interaction with DNA of the antitumor antibiotic olivomycin, Mol. Biol., 1984, vol. 18, no. 4, pp. 1606–1616.
Lombó, F., Menéndez, N., Salas, J.A., et al., The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives, Appl. Microbiol. Biotechnol., 2006, vol. 73, no. 1, pp. 1–14.
Sabín, J.G. and Morís, F., Exploring novel opportunities for aureolic acids as anticancer drugs, Biochem. Pharmacol.: Open Access, 2013, vol. 2, no. 1, pp. 1–3.
Beniaminov, A.D., Chashchina, G.V., Livshits, M.A., et al., Discrimination between G/C binding sites by olivomycin a is determined by kinetics of the drug-dna interaction, Int. J. Mol. Sci., 2020, vol. 21, no. 15, p. 5299.
Tevyashova, A.N., Shtil, A.A., Olsufyeva, E.N., et al., Modification of olivomycin A at the side chain of the aglycon yields the derivative with perspective antitumor characteristics, Bioorg. Med. Chem., 2011, vol. 19, no. 24, pp. 7387–7393.
Samusenko, A.V., Mechanisms of cell death under the action of olivomycin and its derivatives, Cand. Sci. (Med.) Dissertation, Moscow, 2009.
Isagulieva, A.K., Beniaminov, A.D., Tatarskiy, V.V., et al., Targeting gene transcription: mechanisms of antitumor potency of olivomycin A and its preclinical derivative, FEBS Open Bio, 2019, vol. 9, no. S1, p. 153.
Vita, M. and Henriksson, M., The Myc oncoprotein as a therapeutic target for human cancer, Semin. Cancer Biol., 2006, vol. 16, no. 4, pp. 318–330.
Mognol, G.P., de Araujo-Souza, P.S., Robbs, B.K., et al., Transcriptional regulation of the c-Myc promoter by NFAT1 involves negative and positive NFAT-responsive elements, Cell Cycle, 2012, vol. 11, no. 5, pp. 1014–1028.
Previdi, S., Malek, A., Albertini, V., et al., Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts, Gynecol. Oncol., 2010, vol. 118, no. 2, pp. 182–188.
Sleiman, S.F., Langley, B.C., Basso, M., et al., Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration, J. Neurosci., 2011, vol. 31, no. 18, pp. 6858–6870.
Choi, E.-S., Nam, J.-S., Jung, J.-Y., et al., Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer, Sci. Rep., 2014, vol. 4, no. 1, pp. 1–8.
Funding
This work was supported by the Russian Foundation for Basic Research (project no. 19-34-90064).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors declare that they have no conflict of interests. This article does not contain any studies involving animals or human participants performed by any of the authors.
Additional information
Translated by M. Batrukova
Rights and permissions
About this article
Cite this article
Isagulieva, A.K., Soshnikova, N.V. & Shtil, A.A. Inhibition of the c-Myc Oncogene by the Aureolic Acid Group Antibiotics. Dokl Biochem Biophys 500, 308–311 (2021). https://doi.org/10.1134/S1607672921050094
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1607672921050094